SHANGHAI – Sirnaomics Inc. is a biopharma straddling the pacific. While one half is in China, with facilities in Suzhou and Guangzhou, it calls Gaithersburg, Md., its headquarters, where the company first got its start seven years ago. Read More

HONG KONG — A member of a new class of small-molecule drugs has proved to be an attractive candidate for lead optimization in the search for new drugs for the treatment of tuberculosis (TB), researchers from the Novartis Institute for Tropical Diseases (NITD) in Singapore reported in the Jan. 7, 2015, issue of Science Translational Medicine. Read More

HONG KONG – The CFDA approved the country's first-ever orally administrated and subtype-selective histone deacetylase inhibitor (HDACi). Patients in China with relapsed or refractory peripheral T-cell lymphoma (PTCL) now have an alternative treatment other than traditional chemotherapy. Read More

Last week, policymakers, researchers and vaccine developers met at the World Health Organization (WHO) headquarters to review the landscape of current and upcoming Ebola vaccine clinical trials. Their goal, in the words of Director-General Margaret Chan, was to "take stock, plan the next steps and make sure that all partners are working in tandem." Read More

Huya Bioscience International LLC, of San Diego, said the Japanese Pharmaceutical and Medical Devices Agency accepted its accelerated development strategy for cancer drug HBI-8000, in development for the treatment of adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma in Japan. HBI-8000 is a next-generation HDAC inhibitor. Read More